Compare Heron Therapeutics Inc (HRTX) vs Samsara Inc (IOT) Price & Performance

Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.

The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.

Samsara (IOT) trades at $41.71, up 2.96% with strong bullish momentum. The stock shows robust technical strength with bullish moving averages and trades near resistance at $42. Fundamentally, the company demonstrates impressive revenue growth, reaching $1.8B in 2026 with a positive net income turnaround to $91M. Recent Q2 2027 earnings beat expectations with $0.20 EPS versus $0.16 estimate, driven by 30% annual recurring revenue growth and expanding large-customer adoption.

Outlook remains positive with 75% analyst buy ratings and $51.15 consensus target, representing 23% upside. Key opportunities include enterprise standardization trends and AI integration through Samsara MCP. Risks include elevated valuation multiples (P/E 274.8, P/S 13.01) and potential cash flow pressure despite strong operational performance. The stock's recent 72% rally warrants monitoring for sustainability beyond multiple expansion.